Gilead Sciences | GILD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 328.1M 62.31M 2026-03
J&J USD 6.03B 719M 2026-03
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03